Add BrightSurf on Google Email

Less pain, more gain: A new recipe for safer, stronger mRNA vaccines

Researchers at the University of Pennsylvania designed a new recipe for mRNA vaccines by adding phenol groups, which reduce inflammation and improve vaccine effectiveness. The modified lipids improved vaccine performance in various diseases, including COVID-19, cancer, and genetic diseases, with enhanced efficacy and reduced side effects.

SourceUniversity of Pennsylvania School of Engineering and Applied Science·JournalNature Biomedical Engineering·TypeExperimental study·DateJul 18, 2025

Macromolecular gene delivery systems: advancing non-viral therapeutics with synthetic and natural polymers

Gene therapy relies on efficient and safe delivery of therapeutic genes to target cells. Macromolecular carriers, including synthetic and natural polymers, offer biocompatibility, controlled release, and targeted delivery. These systems have shown promise in treating genetic disorders and complex diseases like cancer.

SourceXia & He Publishing Inc.·JournalJournal of Exploratory Research in Pharmacology·DateJul 14, 2025

Gene therapy restored hearing in deaf patients

A new study conducted at Karolinska Institutet reports that gene therapy improved hearing in all ten patients with congenital deafness or severe hearing impairment. The treatment was well-tolerated and showed remarkable results, with the majority of patients recovering some hearing after just one month.

SourceKarolinska Institutet·JournalNature Medicine·TypeExperimental study·DateJul 2, 2025

New gene therapy delivery device could let hospitals create personalized nanomedicines on-demand

A new gene therapy delivery device called NANOSPRESSO could revolutionize how hospitals treat rare diseases by allowing them to create personalized nanomedicines in-house. This democratized approach to precision medicine could boost access to low-cost bespoke gene and RNA therapies, especially in low-resource settings.

SourceFrontiers·JournalFrontiers in Science·TypeSystematic review·DateJun 26, 2025

Scientists discover new approach to gene therapy

Researchers have found a promising new method for gene therapy by bringing dormant genes closer to enhancer switches on the DNA. This 'delete-to-recruit' strategy has potential for treating genetic diseases such as sickle cell disease and beta-thalassemia, offering an alternative to expensive current treatments.

SourceHubrecht Institute·JournalBlood·TypeExperimental study·DateJun 18, 2025

KAIST develops technology for selective RNA modification in living cells and animals

Researchers at KAIST have developed a groundbreaking technology capable of selectively acetylating specific RNA molecules within the human body using the CRISPR-Cas13 system. This breakthrough enables precise, programmable control of RNA function and is expected to open new avenues in RNA-based therapeutic development.

SourceThe Korea Advanced Institute of Science and Technology (KAIST)·JournalNature Chemical Biology·TypeExperimental study·DateJun 11, 2025

Research alert: Alzheimer's gene therapy shows promise in preserving cognitive function

Researchers have developed a gene therapy that targets the root cause of Alzheimer's disease, influencing brain cell behavior to preserve cognitive function. Delivering the treatment at the symptomatic stage preserved hippocampal-dependent memory and altered gene expression in mice, suggesting potential to restore brain health.

SourceUniversity of California - San Diego·JournalSignal Transduction and Targeted Therapy·DateJun 5, 2025

CSMD1 identified as a novel gene in epilepsy

A new study identifies CSMD1 as a novel gene associated with generalized epilepsies, including developmental and epileptic encephalopathy. The research found that CSMD1 variants are more damaging and exhibit lower minor allele frequencies in DEE cases compared to IGE cases.

SourceCompuscript Ltd·JournalGenes & Diseases·DateMay 29, 2025

New study reveals how 5'LysTTT tRNA fragments protect neurons during botulinum toxin exposure

Scientists have uncovered a previously unknown mechanism explaining how neurons survive botulinum neurotoxin type A exposure. The research found that specific tRNA fragments interact with key proteins and RNA molecules involved in regulating ferroptosis, supporting neuronal survival by blocking cell death pathways.

SourceGenomic Press·JournalGenomic Psychiatry·TypeExperimental study·DateMay 20, 2025

World's first patient treated with personalized CRISPR gene editing therapy at Children’s Hospital of Philadelphia

A child diagnosed with a rare genetic disorder has been successfully treated with a customized CRISPR gene editing therapy, showcasing the power of tailored gene editing to treat patients. The infant is now growing well and thriving after receiving three doses of the therapy with no serious side effects.

SourceChildren's Hospital of Philadelphia·JournalNew England Journal of Medicine·TypeCase study·DateMay 15, 2025

Abeona Therapeutics® and Lurie Children's open first center for ZEVASKYNTM gene therapy to treat wounds in painful skin disorder

Lurie Children's is now a Qualified Treatment Center (QTC) for ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB). This therapy promises to provide long-term healing of wounds, reduction in pain and reduced risk of infection.

New gene-editing therapy shows early success in fighting advanced GI cancers

Researchers have successfully tested a CRISPR/Cas9 gene-editing technique to enhance the immune system's fight against advanced gastrointestinal (GI) cancers. The treatment showed encouraging signs of safety and potential effectiveness in patients with stage IV colorectal cancer, halting tumor growth and even achieving complete responses.

SourceUniversity of Minnesota Medical School·JournalThe Lancet Oncology·TypeRandomized controlled/clinical trial·DateMay 2, 2025

New technology facilitates delivery of advanced medicines

Researchers at Karolinska Institutet have developed a technique to deliver gene editors and protein therapeutics to cells using engineered extracellular vesicles. The method shows promising results in animal studies, highlighting the potential for treating genetic diseases and neurological disorders.

SourceKarolinska Institutet·JournalNature Communications·TypeExperimental study·DateApr 30, 2025

A new CAR-T therapy from Sant Pau achieves positive results in a high proportion of patients with a refractory type of lymphoma

A new CAR-T therapy, HSP-CAR30, has achieved positive results in a high proportion of patients with refractory CD30+ lymphoma. The treatment promotes the expansion of memory T cells, leading to durable responses and improved clinical outcomes.

SourceInstitut de Recerca Sant Pau (Sant Pau Research Institute)·JournalBlood·TypeRandomized controlled/clinical trial·DateApr 29, 2025

Triggers 'cellular storm' for smart tumor elimination

Researchers develop nanoparticle-based therapy combining hydroxyl-enriched fullerenol and mTOR inhibitors to disrupt cancer cells' organelle communication system. The approach triggers a synergistic "nanomaterial + metabolic modulation" anticancer strategy, establishing a new hope for treating aggressive cancers.

SourceScience China Press·JournalScience Bulletin·TypeExperimental study·DateApr 27, 2025

Metachromatic Leukodystrophy (MLD) and gene therapy: a game-changing treatment backed by NEJM—Timing Is Everything

A recent study published in the New England Journal of Medicine found that gene therapy can significantly reduce the risk of severe motor and cognitive impairment in children with metachromatic leukodystrophy (MLD). The therapy, administered early, preserves motor function and cognitive abilities in most patients.

SourceFondazione Telethon·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateApr 24, 2025

Breakthrough gene therapy offers hope for rare, deadly heart disease in young men

A team of researchers has developed a gene-therapy strategy to treat arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5), a rare and deadly hereditary disease. The treatment, using adeno-associated viruses, improved cardiac function and prolonged survival in mice with ARVC5-like disease.

SourceCentro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)·JournalCirculation Research·TypeExperimental study·DateApr 8, 2025

New study helps optimize gene therapy

A multidisciplinary team has generated an atlas to optimize gene therapy delivery, providing researchers with insights into the most effective viral vectors for specific tissues. The study identifies AAV4 as a promising vector for vascular and pancreatic applications, offering new possibilities for treating conditions like diabetes.

SourceBaylor College of Medicine·JournalMolecular Therapy·TypeExperimental study·DateApr 1, 2025

Gene therapy reverses symptoms of rare neurological disease in animal models

A recent study demonstrates gene therapy's potential to restore motor capacity in an ultra-rare disease, Megalencephalic Leukoencephalopathy with Subcortical Cysts (MLC), even after symptom onset. The treatment restored normal protein activity, normalizing physiological brain alterations and reversing motor impairments in treated mice.

SourceUniversitat Autonoma de Barcelona·JournalMolecular Therapy·TypeExperimental study·DateMar 31, 2025

IL2RG gene therapy for X-SCID

Researchers have developed a new gene therapy protocol using the SIN-EFS-IL2RG.co vector, which demonstrates safety and efficacy in preclinical studies. The treatment restores immune functions and lacks oncogenicity, paving the way for further clinical trials in X-SCID patients.

SourceCompuscript Ltd·JournalGenes & Diseases·DateMar 13, 2025

New CRISPRs expand upon the original’s abilities

Researchers have discovered new CRISPR-Cas systems with improved efficiency and specificity, including one from dairy cow bacteria that can target specific gene sequences. The new systems have potential applications in human health, biotechnology and environmental fields.

SourceDuke University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateMar 13, 2025

New clinical trial at UTHealth Houston tests gene therapy vector that delivers drug aimed at stopping overactive bladder in patients with spinal cord injury

Researchers are conducting a first-in-human clinical trial to test a modified herpes virus that targets spinal cord nerve cells to treat neurogenic bladder. The therapy, EG110A, aims to block sensory nerve signals causing involuntary bladder contractions and incontinence.

Pusan National University researchers developed an advanced AI model for accelerating therapeutic gene target discovery

The new AI model leverages hypergraphs to quickly and accurately identify therapeutic gene targets for diseases. HIT outperformed existing models in all tested metrics, demonstrating its accuracy in classifying therapeutic gene targets with great precision.

SourcePusan National University·JournalBriefings in Bioinformatics·TypeComputational simulation/modeling·DateMar 5, 2025